Breast and ovarian cancer.

  title={Breast and ovarian cancer.},
  author={R. Wooster and Barbara L. Weber},
  journal={The New England journal of medicine},
  volume={348 23},
Breast and ovarian cancers are among the most common cancers in women. It is known that a woman is at higher risk for breast or ovarian cancer if a family member has had the disease. This article in the Genomic Medicine series provides up-to-date information on the heritable factors associated with these tumors. 

Family history of breast cancer as a risk factor for ovarian cancer in a prospective study

A family history of breast cancer has been associated with increased ovarian cancer risk. However, few studies have assessed risk according to characteristics that suggest an inherited cancer


  • Medicine, Biology
  • 2020
The BRCA1/2 genes are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer, and potentially harmful mutations in the general population occur in an estimated 1 in 300 to 500 women.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Case study: A 46-year-old woman comes to your office to discuss breast cancer screening. She heard a physician on television who mentioned a genetic test that can tell if a woman will get breast

Immunoreactive estrogen receptor in breast tumor and adjacent tissue: Association with clinicopathological characteristics in Indian population

This study has compared the ER levels in breast tumor and adjacent normal tissue in Indian sub‐population to find out the level of ER is different in different racial and ethnic groups.

Endocrine management of breast cancer—biology and current practice

The widening range of adjuvant endocrine options represents an opportunity to prolong patient benefits in the treatment of hormone-receptor-positive breast cancer, and arguments in favour of an impact of postmenopausal oestrogen–progestin therapy on pre-existing tumours derive.

Genetics: breast cancer as an exemplar.

  • R. Hamilton
  • Medicine
    The Nursing clinics of North America
  • 2009

Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer

This study aims to determine the frequency of germline BRCA 1/2 mutations in Turkish women with epithelial ovarian cancer (EOC) and evaluate its relationship with clinicopathological characteristics.

Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1.

This case presents a synchronous and a rare association of a primary ovarian dysgerminoma and a primary breast carcinoma in a patient of 46 years old with a positive immuno-expression for p53 protein and BRCA1 protein.

Identifying and Testing for Hereditary Susceptibility to Common Cancers

The components of providing a hereditary cancer risk assessment with a focus on hereditary breast and ovarian cancer syndrome and hereditary colon cancer are outlined.



Genetic epidemiology of breast and ovarian cancers.

The increased risk of breast and ovarian cancers associated with a family history of these diseases is well established. Yet the relative contributions of biologic inheritance, cultural practices,

Identification of the breast cancer susceptibility gene BRCA2

The identification of a gene in which six different germline mutations in breast cancer families that are likely to be due to BRCA2 are detected, and results indicate that this is the BRC a2 gene.

Putting the risk of breast cancer in perspective.

This study highlights the need to understand more fully the rationale behind the continued use of mammography, as well as the need for further research into its use in the diagnosis and treatment of breast cancer.

A systematic review and meta‐analysis of family history and risk of ovarian cancer

The relative risk and lifetime risk of ovarian cancer in women with various categories of family history are estimated with respect to age, sex, and family history.

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

This analysis localized a second breast cancer susceptibility locus, BRCA2, to a 6-centimorgan interval on chromosome 13q12-13, which preliminary evidence suggests suggests confers a high risk of breast cancer but does not confer a substantially elevated risk of ovarian cancer.

Breast cancer detection guidelines for women aged 40 to 49 years: Rationale for the american cancer society reaffirmation of recommendations

The process and some of the evidence the American Cancer Society has relied upon in reaffirming its recommended guidelines for early breast cancer detection are reviewed.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.

Age‐related differences in breast carcinoma knowledge, beliefs, and perceived risk among women visiting an academic general medicine practice

This study assessed whether age‐related differences in breast carcinoma knowledge and perceived risk exist among women in a primary care setting and whether these women's beliefs about the best age

Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.

The results suggest that the majority of breast cancer families with less than four cases and no ovarian cancer are not due to rare highly penetrant genes such as BRCA1 but are more likely to be due either to chance or to more common genes of lower penetrance.

Genetic analysis of breast cancer in the cancer and steroid hormone study.

Segregation analysis and goodness-of-fit tests of genetic models provide evidence for the existence of a rare autosomal dominant allele (q = .0033) leading to increased susceptibility to breast cancer.